Both PRDX1 and ANXA2 are elevated in stage I endometrial cancer (58), and ANXA2 has been suggested as a potential biomarker for recurrent endometrial cancer (59) and in ovarian cancer progression (regulation of β-catenin-driven epithelial-mesenchymal transition) (60). Here, ANXA2 is linked to endometrial cancer.